$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000165731224000007 Filed on February 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cost Of Revenue		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Gross Profit Margin
Selling, General & Admin	$20.43M	$14.97M	$50.35M
YoY Change	113.08%	79.89%	89.45%
% of Gross Profit
Research & Development	$6.764M	$4.122M	$17.22M
YoY Change	-46.36%	-39.72%	-65.07%
% of Gross Profit
Depreciation & Amortization	$263.0K	$208.0K	$677.0K
YoY Change	67.52%	37.75%	6.45%
% of Gross Profit
Operating Expenses	$27.20M	$19.09M	$67.57M
YoY Change	22.52%	25.94%	-10.93%
Operating Profit	-$27.20M	-$19.09M	-$67.57M
YoY Change	22.52%	26.88%	-10.8%
Interest Expense	$1.586M	$3.875M	$2.057M
YoY Change	441.3%	-16.58%	294.82%
% of Operating Profit
Other Income/Expense, Net	$2.158M	$1.034M	$13.67M
YoY Change	-61.66%	29.9%	87.26%
Pretax Income	-$25.04M	-$14.19M	-$53.90M
YoY Change	51.12%	36.09%	-21.26%
Income Tax	$754.0K	-$53.00K	$474.0K
% Of Pretax Income
Net Earnings	-$25.79M	-$14.13M	-$54.37M
YoY Change	54.06%	35.22%	-20.86%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.04		-$0.09
Diluted Earnings Per Share	-$0.04	-$0.02	-$0.09
COMMON SHARES
Basic Shares Outstanding	646.5M shares	639.5M shares	634.1M shares
Diluted Shares Outstanding	645.7M shares		634.1M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$254.9M	$271.8M	$271.8M
YoY Change	-12.54%	19.29%	19.29%
Cash & Equivalents	$254.9M	$271.8M	$271.8M
Short-Term Investments
Other Short-Term Assets	$1.875M	$3.365M	$6.982M
YoY Change	-9.55%	-0.68%	18.6%
Inventory		$0.00
Prepaid Expenses	$3.622M	$3.617M
Receivables		$0.00
Other Receivables
Total Short-Term Assets	$271.8M	$289.7M	$289.7M
YoY Change	-11.42%	19.22%	19.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.00K	$24.00K	$2.871M
YoY Change	83.33%	-67.12%	209.71%
Goodwill	$545.0K	$545.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M	$15.00M
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$18.07M	$18.42M	$18.42M
YoY Change	11.18%	11.8%	11.8%
TOTAL ASSETS
Total Short-Term Assets	$271.8M	$289.7M	$289.7M
Total Long-Term Assets	$18.07M	$18.42M	$18.42M
Total Assets	$289.9M	$308.1M	$308.1M
YoY Change	-10.28%	18.75%	18.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.651M	$3.492M	$3.492M
YoY Change	-35.73%	20.0%	20.0%
Accrued Expenses	$8.269M	$3.585M	$4.765M
YoY Change	-53.29%	-73.93%	-66.97%
Deferred Revenue		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.77M	$8.692M	$8.692M
YoY Change	-44.3%	-54.32%	-54.32%
LONG-TERM LIABILITIES
Long-Term Debt	$48.55M	$48.37M	$48.37M
YoY Change	145.07%	395.23%	395.23%
Other Long-Term Liabilities	$1.604M	$1.775M	$1.775M
YoY Change	2367.69%	765.85%	765.85%
Total Long-Term Liabilities	$50.15M	$50.15M	$50.15M
YoY Change	152.34%	402.85%	402.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.77M	$8.692M	$8.692M
Total Long-Term Liabilities	$50.15M	$50.15M	$50.15M
Total Liabilities	$64.92M	$58.84M	$58.84M
YoY Change	39.93%	102.89%	102.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$414.4M	-$388.4M
YoY Change	18.37%	16.6%
Common Stock	$42.77M	$42.77M
YoY Change	2.44%	5.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.282M	$1.517M
YoY Change	6.13%	-2.07%
Treasury Stock Shares
Shareholders Equity	$225.0M	$249.3M	$249.3M
YoY Change
Total Liabilities & Shareholders Equity	$289.9M	$308.1M	$308.1M
YoY Change	-10.28%	18.75%	18.75%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$25.79M	-$14.13M	-$54.37M
YoY Change	54.06%	35.22%	-20.86%
Depreciation, Depletion And Amortization	$263.0K	$208.0K	$677.0K
YoY Change	67.52%	37.75%	6.45%
Cash From Operating Activities	-$13.61M	-$10.40M	-$50.22M
YoY Change	135.39%	34.43%	-16.1%
INVESTING ACTIVITIES
Capital Expenditures	$16.00K	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$16.00K	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$56.91M
YoY Change			-62.01%
Debt Paid & Issued, Net			$0.00
YoY Change			-100.0%
Cash From Financing Activities	-$3.123M	24.01M	$92.87M
YoY Change	-104.55%	818.59%	-34.05%
NET CHANGE
Cash From Operating Activities	-$13.61M	-10.40M	-$50.22M
Cash From Investing Activities	-$16.00K	0.000	$0.00
Cash From Financing Activities	-$3.123M	24.01M	$92.87M
Net Change In Cash	-$16.89M	13.61M	$43.95M
YoY Change	-126.56%	-365.61%	-44.69%
FREE CASH FLOW
Cash From Operating Activities	-$13.61M	-$10.40M	-$50.22M
Capital Expenditures	$16.00K	$0.00	$0.00
Free Cash Flow	-$13.63M	-$10.40M	-$50.22M
YoY Change	135.66%	34.43%	-16.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13674000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7302000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53895000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68448000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
CY2023Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	59000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3558000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	0	usd
CY2022	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2023	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	31115926	shares
CY2017Q4	vrna	Class Of Warrant Or Right Issue Price Of Warrants Or Rights ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights	1.4365
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.4	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31003155	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2022Q4	vrna	Class Of Warrant Or Right Intrinsic Value ClassOfWarrantOrRightIntrinsicValue	0	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y3M29D
CY2022Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2246000	usd
CY2022	vrna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Fair Value Adjustment FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment	-2246000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38067
CY2023	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
CY2023	dei	Entity Address Country EntityAddressCountry	GB
CY2023	dei	Country Region CountryRegion	44
CY2023	dei	City Area Code CityAreaCode	203
CY2023	dei	Local Phone Number LocalPhoneNumber	283 4200
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
CY2023	dei	Trading Symbol TradingSymbol	VRNA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	31115926	shares
CY2017Q4	vrna	Class Of Warrant Or Right Issue Price Of Warrants Or Rights ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights	1.4365
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.4	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31003155	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2022Q4	vrna	Class Of Warrant Or Right Intrinsic Value ClassOfWarrantOrRightIntrinsicValue	0	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y3M29D
CY2022Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	0	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2246000	usd
CY2022	vrna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Fair Value Adjustment FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment	-2246000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38067
CY2023	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
CY2023	dei	Entity Address Country EntityAddressCountry	GB
CY2023	dei	Country Region CountryRegion	44
CY2023	dei	City Area Code CityAreaCode	203
CY2023	dei	Local Phone Number LocalPhoneNumber	283 4200
CY2023	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
CY2023	dei	Trading Symbol TradingSymbol	VRNA
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1500000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	646524958	shares
CY2023	dei	Auditor Firm AuditorFirmId	876
CY2023	dei	Auditor Firm AuditorFirmId	876
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Reading, United Kingdom
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	271772000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227827000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3617000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2499000	usd
CY2023Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	10954000	usd
CY2022Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	9282000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3365000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3388000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	289708000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	242996000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2847000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	854000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	18416000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16472000	usd
CY2023Q4	us-gaap	Assets Assets	308124000	usd
CY2022Q4	us-gaap	Assets Assets	259468000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3492000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2910000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1180000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	283000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8692000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19029000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48374000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9768000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1775000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	205000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	50149000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9973000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	58841000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	29002000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1500000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	646524958	shares
CY2023	dei	Auditor Firm AuditorFirmId	876
CY2023	dei	Auditor Firm AuditorFirmId	876
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Reading, United Kingdom
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	271772000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227827000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3617000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2499000	usd
CY2023Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	10954000	usd
CY2022Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	9282000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3365000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3388000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	289708000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	242996000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2847000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	854000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	18416000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16472000	usd
CY2023Q4	us-gaap	Assets Assets	308124000	usd
CY2022Q4	us-gaap	Assets Assets	259468000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3492000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2910000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1180000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	675000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	283000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	435000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1409000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8692000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19029000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48374000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9768000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1775000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	50149000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9973000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	58841000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	29002000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667659630	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631338246	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	643536094	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	606301054	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	42771000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40526000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	601063000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	529187000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1517000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1549000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388433000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333097000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	308124000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259468000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	346000	usd
CY2023	us-gaap	Gross Profit GrossProfit	0	usd
CY2022	us-gaap	Gross Profit GrossProfit	112000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49283000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50353000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26579000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	67569000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	75862000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-67569000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-75750000	usd
CY2023	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1104000	usd
CY2022	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	9634000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2057000	usd
CY2022	us-gaap	Interest Expense InterestExpense	521000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1866000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	474000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	634142660	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	634142660	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	529071526	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	529071526	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	667659630	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631338246	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	643536094	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	606301054	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	42771000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40526000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	601063000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	529187000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1517000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1549000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388433000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333097000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	308124000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259468000	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Revenues Revenues	458000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	346000	usd
CY2023	us-gaap	Gross Profit GrossProfit	0	usd
CY2022	us-gaap	Gross Profit GrossProfit	112000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17216000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49283000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50353000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26579000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	67569000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	75862000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-67569000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-75750000	usd
CY2023	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	1104000	usd
CY2022	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	9634000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-815000	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	12761000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	2821000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2057000	usd
CY2022	us-gaap	Interest Expense InterestExpense	521000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1866000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3817000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	474000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	634142660	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	634142660	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	529071526	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	529071526	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1372000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14121000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4723000	usd
CY2022	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	-128000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1949000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19012000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4389000	usd
CY2023	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	295000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1866000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3817000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	116000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	80000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	106000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-815000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	19012000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14121000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	677000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	636000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1118000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1538000	usd
CY2023	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	1104000	usd
CY2022	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-3964000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-777000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1325000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	486000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7146000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10351000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8504000	usd
CY2023	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-591000	usd
CY2022	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-597000	usd
CY2023	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-1037000	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	136000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-960000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1196000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50222000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59862000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56909000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149797000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9533000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9996000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1372000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14121000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4723000	usd
CY2022	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	-128000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1949000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19012000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4389000	usd
CY2023	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	295000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	249283000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1866000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3817000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	116000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	80000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	106000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-815000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	19012000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14121000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	677000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	636000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1118000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1538000	usd
CY2023	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	1104000	usd
CY2022	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-3964000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-777000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1325000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7146000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10351000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8504000	usd
CY2023	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-591000	usd
CY2022	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-597000	usd
CY2023	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	-1037000	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	136000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-960000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1196000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50222000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59862000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56909000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149797000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9533000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	9996000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	usd
CY2023	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	28712000	usd
CY2022	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	0	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	12000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	245000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5000000	usd
CY2023	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	usd
CY2022	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	850000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4685000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4723000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1949000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1372000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92869000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	140818000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1298000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1480000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	43945000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	79447000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271772000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1245000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	120000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2006000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	348000	usd
CY2023	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2023Q2	vrna	Payments For Application Fees PaymentsForApplicationFees	3200000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388400000	usd
CY2022Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	80696	shares
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.86
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2023	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	28712000	usd
CY2022	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	0	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	12000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	245000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5000000	usd
CY2023	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	usd
CY2022	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	850000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4685000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4723000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1949000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1372000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92869000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	140818000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1298000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1480000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	43945000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	79447000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271772000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1245000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	120000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2006000	usd
CY2023	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2023Q2	vrna	Payments For Application Fees PaymentsForApplicationFees	3200000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388400000	usd
CY2022Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	80696	shares
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.86
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds. Our deposits at these institutions may exceed insured limits, however the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds. Our deposits at these institutions may exceed insured limits, however the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div>
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.11
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.04
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y3M18D
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y6M
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1175000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	842000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	788000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	784000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	634000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2955000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.04
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1822688	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.75
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19276496	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.22
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.11
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.04
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y3M18D
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y6M
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1175000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	842000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	788000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	784000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3589000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	634000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2955000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	usd
CY2023Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	752000	usd
CY2022Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	12314000	usd
CY2023Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2039000	usd
CY2022Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1364000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	794000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	74000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	50000000	usd
CY2023Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12695200	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9024000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.90
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	620016	shares
CY2023Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	752000	usd
CY2022Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	12314000	usd
CY2023Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	2039000	usd
CY2022Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1364000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	794000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	74000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3585000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	50000000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	50000000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19012000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14121000	usd
CY2023Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12695200	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9024000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.90
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	620016	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.04
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1822688	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.75
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19276496	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.22
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39412000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7376000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.46
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	464680	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.89
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	240000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.07
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1258192	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.55
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24689624	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24022000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12904640	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.30
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15574000	usd
CY2023Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1861000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2413000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1949000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1372000	usd
CY2023	vrna	Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue	13200000	usd
CY2022	vrna	Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue	5900000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	38347352	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.97
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.03
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.96
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	34542344	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.66
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.10
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.99
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	19502624	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.14
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39412000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7376000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.46
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	464680	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.89
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	240000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.07
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1258192	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.55
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24689624	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.56
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24022000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12904640	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.30
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	15574000	usd
CY2023Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1861000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2413000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1949000	usd
CY2023	vrna	Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue	13200000	usd
CY2022	vrna	Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue	5900000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	38347352	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.97
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.03
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.96
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	34542344	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.66
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.10
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.99
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	19502624	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.14
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	7429000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3868000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61324000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-72316000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53895000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68448000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	474000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	253000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	253000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	474000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.235
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.080
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	600000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	7429000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3868000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61324000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-72316000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53895000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68448000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	474000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	253000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	474000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	253000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	474000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.018
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.041
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.080
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.235
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.080
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.018
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.041
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.080
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.054
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.021
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.181
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.116
CY2023	vrna	Effective Income Tax Rate Reconciliation Capital Allowances Percent EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent	0.004
CY2022	vrna	Effective Income Tax Rate Reconciliation Capital Allowances Percent EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent	-0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009
CY2023Q4	vrna	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	53851000	usd
CY2022Q4	vrna	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	34565000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	34565000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54012000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38893000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	47793000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	32700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7548000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11964000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	21000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-516000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	109374000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83041000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	55523000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	48476000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	216000000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	155600000	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2023Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	0	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	0	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.054
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.021
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.181
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.116
CY2023	vrna	Effective Income Tax Rate Reconciliation Capital Allowances Percent EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent	0.004
CY2022	vrna	Effective Income Tax Rate Reconciliation Capital Allowances Percent EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent	-0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2023Q4	vrna	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	53851000	usd
CY2022Q4	vrna	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	34565000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	53851000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	34565000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54012000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38893000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	47793000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	32700000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7548000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11964000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	21000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-516000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	109374000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83041000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	55523000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	48476000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	216000000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	155600000	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2023Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	0	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	0	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2023Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	634142660	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	634142660	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	529071526	shares
CY2023Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54369000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	634142660	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	634142660	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	529071526	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	529071526	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54900000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	53800000	shares
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	6900000	usd
CY2023Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1500000	usd
CY2023Q4	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	2100000	usd
CY2023Q2	vrna	Loss Contingency Accrual Reversal Of Research And Development Costs LossContingencyAccrualReversalOfResearchAndDevelopmentCosts	6300000	usd
CY2023	vrna	Loss Contingency Accrual Reversal Of Research And Development Costs LossContingencyAccrualReversalOfResearchAndDevelopmentCosts	1500000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	529071526	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54900000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	53800000	shares
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	6900000	usd
CY2023Q1	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	1500000	usd
CY2023Q4	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	2100000	usd
CY2023Q2	vrna	Loss Contingency Accrual Reversal Of Research And Development Costs LossContingencyAccrualReversalOfResearchAndDevelopmentCosts	6300000	usd
CY2023	vrna	Loss Contingency Accrual Reversal Of Research And Development Costs LossContingencyAccrualReversalOfResearchAndDevelopmentCosts	1500000	usd

Files In Submission

Name	View Source	Status
0001657312-24-000007-index-headers.html	Edgar Link	pending
0001657312-24-000007-index.html	Edgar Link	pending
0001657312-24-000007.txt	Edgar Link	pending
0001657312-24-000007-xbrl.zip	Edgar Link	pending
consentletter-fy23.htm	Edgar Link	pending
exhibit211q423.htm	Edgar Link	pending
exhibit311q423.htm	Edgar Link	pending
exhibit312q423.htm	Edgar Link	pending
exhibit321q423.htm	Edgar Link	pending
exhibit322q423.htm	Edgar Link	pending
exhibitveronapharma-claw.htm	Edgar Link	pending
exhibitveronapharma-claw001.jpg	Edgar Link	pending
exhibitveronapharma-claw002.jpg	Edgar Link	pending
exhibitveronapharma-claw003.jpg	Edgar Link	pending
exhibitveronapharma-claw004.jpg	Edgar Link	pending
exhibitveronapharma-claw005.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trcveronacommercialsuppl.htm	Edgar Link	pending
trcveronacommercialsuppl001.jpg	Edgar Link	pending
trcveronacommercialsuppl002.jpg	Edgar Link	pending
trcveronacommercialsuppl003.jpg	Edgar Link	pending
trcveronacommercialsuppl004.jpg	Edgar Link	pending
trcveronacommercialsuppl005.jpg	Edgar Link	pending
trcveronacommercialsuppl006.jpg	Edgar Link	pending
trcveronacommercialsuppl007.jpg	Edgar Link	pending
trcveronacommercialsuppl008.jpg	Edgar Link	pending
trcveronacommercialsuppl009.jpg	Edgar Link	pending
trcveronacommercialsuppl010.jpg	Edgar Link	pending
trcveronacommercialsuppl011.jpg	Edgar Link	pending
trcveronacommercialsuppl012.jpg	Edgar Link	pending
trcveronacommercialsuppl013.jpg	Edgar Link	pending
trcveronacommercialsuppl014.jpg	Edgar Link	pending
trcveronacommercialsuppl015.jpg	Edgar Link	pending
trcveronacommercialsuppl016.jpg	Edgar Link	pending
trcveronacommercialsuppl017.jpg	Edgar Link	pending
trcveronacommercialsuppl018.jpg	Edgar Link	pending
trcveronacommercialsuppl019.jpg	Edgar Link	pending
trcveronacommercialsuppl020.jpg	Edgar Link	pending
trcveronacommercialsuppl021.jpg	Edgar Link	pending
trcveronacommercialsuppl022.jpg	Edgar Link	pending
trcveronacommercialsuppl023.jpg	Edgar Link	pending
trcveronacommercialsuppl024.jpg	Edgar Link	pending
trcveronacommercialsuppl025.jpg	Edgar Link	pending
trcveronacommercialsuppl026.jpg	Edgar Link	pending
trcveronacommercialsuppl027.jpg	Edgar Link	pending
trcveronacommercialsuppl028.jpg	Edgar Link	pending
trcveronacommercialsuppl029.jpg	Edgar Link	pending
trcveronacommercialsuppl030.jpg	Edgar Link	pending
trcveronacommercialsuppl031.jpg	Edgar Link	pending
trcveronacommercialsuppl032.jpg	Edgar Link	pending
trcveronacommercialsuppl033.jpg	Edgar Link	pending
trcveronacommercialsuppl034.jpg	Edgar Link	pending
trcveronacommercialsuppl035.jpg	Edgar Link	pending
trcveronacommercialsuppl036.jpg	Edgar Link	pending
trcveronacommercialsuppl037.jpg	Edgar Link	pending
verona-10xkxex451489333021.htm	Edgar Link	pending
vrna-20231231.htm	Edgar Link	pending
vrna-20231231.xsd	Edgar Link	pending
vrna-20231231_g1.jpg	Edgar Link	pending
vrna-20231231_g10.jpg	Edgar Link	pending
vrna-20231231_g11.jpg	Edgar Link	pending
vrna-20231231_g12.jpg	Edgar Link	pending
vrna-20231231_g13.jpg	Edgar Link	pending
vrna-20231231_g2.jpg	Edgar Link	pending
vrna-20231231_g3.jpg	Edgar Link	pending
vrna-20231231_g4.jpg	Edgar Link	pending
vrna-20231231_g5.jpg	Edgar Link	pending
vrna-20231231_g6.jpg	Edgar Link	pending
vrna-20231231_g7.jpg	Edgar Link	pending
vrna-20231231_g8.jpg	Edgar Link	pending
vrna-20231231_g9.jpg	Edgar Link	pending
vrna-20231231_def.xml	Edgar Link	unprocessable
vrna-20231231_pre.xml	Edgar Link	unprocessable
vrna-20231231_lab.xml	Edgar Link	unprocessable
vrna-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
vrna-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2024 Q1 Form 10-K Financial Statement

#000165731224000007 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2024 Q1 Form 10-K Financial Statement

#000165731224000007 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna